Gamma Medica Announces Pennsylvania’s First Clinical Installation of LumaGEM® Molecular Breast Imaging System at Einstein Medical Center Philadelphia

CathWorks FFRangio™ System Receives National Reimbursement Approval in Japan

CathWorks announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the application to provide reimbursement for the CathWorks FFRangio™ System,...

Levine Leichtman Capital Partners Sells FlexXray

Levine Leichtman Capital Partners ("LLCP"), a Los Angeles-based private equity firm, announced today that it has sold its portfolio company FlexXray Holdings, LLC ("FlexXray" or...

 

Secondary screening method significantly improves early cancer detection for women with dense breast tissue

Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Einstein Medical Center Philadelphia has installed Pennsylvania’s first clinical LumaGEM® Molecular Breast Imaging system. MBI is a proven, effective supplementary screening method to standard mammography and/or tomosynthesis (3D mammography), significantly increasing early detection of breast cancer in women.1

In the U.S., approximately 50 percent of women are reported to have dense breast tissue, but many women do not realize they have dense breasts or the implications dense breast tissue has on increasing their lifetime risk of breast cancer.2 Dense breast tissue and cancer both appear white on mammograms making it difficult to distinguish between the two. It’s like trying to find a snowflake in a snowstorm, which can lead to false negatives or delayed diagnoses.3

Philip Croxford, president and CEO of Gamma Medica highlights, The new installation of the LumaGEM MBI system at Einstein Medical Center Philadelphia now gives women access to a clinically superior diagnostic and secondary breast screening method.  He went on to say,  “LumaGEM MBI provides the opportunity for personalized breast screenings in women who are at higher risk of being diagnosed with breast cancer, in effect raising the standard in breast cancer detection. We look forward to continued collaboration with the hospital and its affiliates with the goal of improving the lives of women in the area.”

A breakthrough retrospective clinical study published in the August issue of the American Journal of Roentgenologyconfirmed MBI’s high incremental cancer detection rate: MBI was able to detect 7.7 cancers per 1,000 women screened that were not found using mammography. Approximately 85 percent of these cancers were invasive and 82 percent of the invasive cancers were also node negative, meaning they were detected at an earlier stage and presented a better prognosis.4 While mammograms may fail to detect breast tumors due to tissue density, MBI highlights metabolic activity in these tumors despite breast density, leading to an earlier diagnosis.

“I’m excited about adding this technology to our program so we can help screen so many of our patients who have dense breast tissue,” said Debra Somers Copit, MD, director of breast imaging for Einstein Healthcare Network.

spot_img

DON'T MISS

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.